

Yitong Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4454756/publications.pdf>

Version: 2024-02-01

27
papers

1,162
citations

471061

17
h-index

552369

26
g-index

27
all docs

27
docs citations

27
times ranked

2010
citing authors

#	ARTICLE	IF	CITATIONS
1	Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1779-1784.	1.7	248
2	Drugs as CYP3A Probes, Inducers, and Inhibitors. <i>Drug Metabolism Reviews</i> , 2007, 39, 699-721.	1.5	171
3	Electron spin resonance spectroscopy for the study of nanomaterial-mediated generation of reactive oxygen species. <i>Journal of Food and Drug Analysis</i> , 2014, 22, 49-63.	0.9	163
4	Oxidative demethylation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4391-4401.	1.6	86
5	An approach to identifying sequential metabolites of a typical phenylethanoid glycoside, echinacoside, based on liquid chromatography-ion trap-time of flight mass spectrometry analysis. <i>Talanta</i> , 2009, 80, 572-580.	2.9	65
6	A transcriptomic study suggesting human iPSC-derived hepatocytes potentially offer a better in vitro model of hepatotoxicity than most hepatoma cell lines. <i>Cell Biology and Toxicology</i> , 2017, 33, 407-421.	2.4	61
7	Effects of Short-Term and Long-Term Pretreatment of <i>Schisandra</i> Lignans on Regulating Hepatic and Intestinal CYP3A in Rats. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2399-2407.	1.7	47
8	Characterization of Pharmacokinetic Profiles and Metabolic Pathways of 20(S)-Ginsenoside Rh1 in vivo and in vitro. <i>Planta Medica</i> , 2009, 75, 797-802.	0.7	41
9	Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. <i>Acta Pharmacologica Sinica</i> , 2006, 27, 1253-1258.	2.8	32
10	Inhibition of monoamine oxidase (MAO) by β -carbolines and their interactions in live neuronal (PC12) and liver (HuH-7 and MH1C1) cells. <i>Toxicology in Vitro</i> , 2014, 28, 403-410.	1.1	29
11	Regioselective Glucuronidation of Tanshinone IIa after Quinone Reduction: Identification of Human UDP-Glucuronosyltransferases, Species Differences, and Interaction Potential. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1132-1140.	1.7	28
12	A fluorescence assay for measuring acetylcholinesterase activity in rat blood and a human neuroblastoma cell line (SH-SY5Y). <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 76, 15-22.	0.3	28
13	CYP3A4 inhibition by <i>Psoralea corylifolia</i> and its major components in human recombinant enzyme, differentiated human hepatoma HuH-7 and HepaRG cells. <i>Toxicology Reports</i> , 2015, 2, 530-534.	1.6	21
14	Incorporation of absorption and metabolism into liver toxicity prediction for phytochemicals: A tiered in silico QSAR approach. <i>Food and Chemical Toxicology</i> , 2018, 118, 409-415.	1.8	21
15	Liver toxicity of anthraquinones: A combined in vitro cytotoxicity and in silico reverse dosimetry evaluation. <i>Food and Chemical Toxicology</i> , 2020, 140, 111313.	1.8	21
16	Effects of dietary phenolics and botanical extracts on hepatotoxicity-related endpoints in human and rat hepatoma cells and statistical models for prediction of hepatotoxicity. <i>Food and Chemical Toxicology</i> , 2011, 49, 1820-1827.	1.8	19
17	Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells. <i>Cell Biology and Toxicology</i> , 2015, 31, 221-230.	2.4	19
18	Use of the Combination Index to determine interactions between plant-derived phenolic acids on hepatotoxicity endpoints in human and rat hepatoma cells. <i>Phytomedicine</i> , 2013, 20, 461-468.	2.3	15

#	ARTICLE	IF	CITATIONS
19	Anthraquinones inhibit cytochromes P450 enzyme activity in silico and in vitro. <i>Journal of Applied Toxicology</i> , 2021, 41, 1438-1445.	1.4	11
20	Identification of acetylcholinesterase inhibitors using homogenous cell-based assays in quantitative high-throughput screening platforms. <i>Biotechnology Journal</i> , 2017, 12, 1600715.	1.8	10
21	Cytochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements. <i>Drug Testing and Analysis</i> , 2016, 8, 307-310.	1.6	9
22	Determination of 20(S)-Ginsenoside Rh1 and its Aglycone 20(S)-Protopanaxatriol in Rat Plasma by Sensitive LC-APCI-MS Method and its Application to Pharmacokinetic Study. <i>European Journal of Mass Spectrometry</i> , 2009, 15, 57-65.	0.5	6
23	Sex hormone modulation of both induction and inhibition of CYP1A by genistein in HepG2/C3A cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2015, 51, 426-431.	0.7	6
24	In silico evaluation of pharmacokinetics and acute toxicity of withanolides in Ashawagandha. <i>Phytochemistry Letters</i> , 2022, 47, 130-135.	0.6	3
25	Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells. <i>Methods in Molecular Biology</i> , 2016, 1473, 63-70.	0.4	1
26	Use In Silico and In Vitro Methods to Screen Hepatotoxic Chemicals and CYP450 Enzyme Inhibitors. <i>Methods in Molecular Biology</i> , 2022, 2474, 189-198.	0.4	1
27	Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells. <i>Methods in Molecular Biology</i> , 2022, 2474, 39-46.	0.4	0